Signum Biosciences
Dr. Stock has been a professor at Princeton University for over 40 year and more than 60 years collectively in academia where his research has built the foundations for ingredient development at Signum Biosciences, which he started in 2003 with his son and CEO Maxwell Stock.
This person is not in the org chart
This person is not in any offices
Signum Biosciences
2 followers
Signum Biosciences develops small molecule therapeutics derived from its STM platform to modulate signal transduction imbalances.